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Abstract
Background: Several different interventions have been examined to alleviate pain and reduce frequency of
trigeminal neuralgia (TN) paroxysms. However, some patients continue to have persistent or recurrent painful
attacks. Using a systematic review and meta-analysis approach, we aimed to synthesize evidence from published
randomized controlled trials (RCTs) regarding safety and efficacy of botulinum toxin type A (BTX-A) as a possible
emerging choice of treatment for TN.
Methods: We conducted an electronic search in 10 databases/electronic search engines to access relevant
publications. All articles in all languages reporting RCTs on the efficacy and safety of BTX-A in the treatment of TN
were included for systematic review and meta-analysis.
Results: A total of four RCTs (n = 178) were identified for final meta-analysis. The overall effect favored BTX-A versus
placebo in terms of proportion of responders (risk ratio RR = 2.87, 95 % confidence interval CI [1.76, 4.69], p <0.0001)
with no significant detected heterogeneity (p = 0.31; I2 = 4 %). Paroxysms frequency per day was significantly lower
for BTX-A group (mean difference MD = -29.79, 95 % CI [-38.50,–21.08], p <0.00001) with no significant
heterogeneity (p = 0.21; I2 = 36 %).
Conclusion: Despite limited data, our results suggest that BTX-A may be an effective and safe treatment option for
patients with TN. Further larger and well-designed RCTs are encouraged to translate these findings into better
clinical outcome and better quality of life for TN patients.
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Introduction
Trigeminal neuralgia (TN) is a characteristic pain along
the distribution of one or more branches of the trigemi-
nal nerve. The pain is usually unilateral and described as
severe, sharp, and stabbing electric shock-like pain.
Consequently, quality of life of TN patients is pro-
foundly worsened due to impairment of daily life activ-
ities, thus patients are at a high risk of depression and
other psychiatric disorders [1–3]. Epidemiological stud-
ies showed that approximately 4 to 28.9/100,000 persons
worldwide experience TN [4, 5]. Moreover, a recent
large retrospective cohort study reported increased risk
of depression and anxiety disorders in TN patients [6].
To date, the mechanisms underlying the pathogenesis of
TN are still controversial; however, the microvascular
compression is the most common hypothesis [7, 8].
Recently, therapeutic and surgical approaches have
been evolved to alleviate the neuropathic pain and
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improve quality of life in TN patients. Oral antiepileptic
drugs, including carbamazepine, remain the first line of
treatment [9]. Yet, 25–50 % of cases became refractory
to the drug therapy [10]. Invasive operations such as
neurovascular decompression [11], gamma knife radio-
surgery [12], partial sensory rhizotomy, and percutan-
eous radiofrequency thermo-coagulation [13] may be
required in some intractable cases. Then again, Surgical
interventions occasionally effect severe and often un-
treatable complications that might be even worse than
the primary TN [14]. Moreover, a study reported recur-
rence of the pain in about half of the patients within
2 years of percutaneous radiofrequency rhizotomy [15].
Recently, a cross specialty management program for TN
patients was implemented in a tertiary referral center for
headache and pain [16]. The program involved collabor-
ation between neurologists, neuroradiologists, and neu-
rosurgeons and showed promising in terms of feasibility
and utility in management of TN [16].
In light of the evidence currently available, it seems
fair to argue that there is an overwhelming need for de-
veloping much safer, better tolerated, and efficacious
treatment for TN. Botulinum toxin type A (BTX-A) is a
neurotoxin derived from Clostridium botulinum [17]. It
acts via inhibiting release of acetylcholine at neuromus-
cular junctions, causing relaxation of the muscle [18,
19]. BTX-A has been shown to be a promising option
for treatment of headache [20, 21]. It was further ap-
proved by the US Food and Drug Administration (FDA)
for prevention of headache in adults suffering from
chronic migraine.
In 2002, Micheli and colleagues [22] reported success-
ful relief of twitching and pain in a patient with TN-
associated hemifacial spasm. Since then, several clinical
trials have been investigating the safety and efficacy of
BTX-A in TN. The drug showed favorable effects in
many reports. Having said that, the majority of studies
were at a high risk of bias, aside from the small sample
size included in each trial. This necessitates a confirma-
tory evidence to be released asserting the notion that
BTX-A may be safe and effective option for management
of TN.
The aim of this study is to provide a clear-cut evi-
dence regarding safety and efficacy of botulinum
toxin type A in trigeminal neuralgia from published




The study strictly followed the recommendation of Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement (Additional file 1:
Table S1). During September and October, we
established the protocol and registered our study with
PROSPERO, University of York (CRD42015026861).
Ten electronic search engines/libraries were systematic-
ally searched for relevant publications, including
PubMed, Scopus, Web of Science, Google Scholar, Vir-
tual Health Library (VHL), WHO Global Health Library
(GHL), ClinicalTrials, POPLINE, System for Information
on Grey Literature in Europe (SIGLE), and the New
York Academy of Medicine (NYAM). Except for Google
Scholar, the search term for all other libraries was as fol-
lows: (botulinum OR onabotulinumtoxinA OR onabotu-
linum OR botox OR botulinus) AND ((trigeminal
neuralgia) OR prosopalgia OR (Fothergill's disease) OR
(tic doloureux)). For Google Scholar, we used the ad-
vanced setting in which “trigeminal neuralgia” was filled
in “with all of the words” and “botulinum botulinus
botox onabotulinum toxin A onabotulinum” for “with at
least one of the words”. Additionally, we conducted a
manual search by reviewing the citations within the in-
cluded publications and reviewing the related references
presented in PubMed.
Selection criteria and title and abstract screening
Search results from the ten aforementioned search en-
gines/libraries were imported into Endnote X7 (Thomp-
son Reuter, CA, USA) for duplicates deletion. Two
reviewers independently screened the references using
the predetermined eligibility criteria. The inclusion cri-
teria were: (i) randomized-controlled trials (RCTs)
reporting efficacy and safety of botulinum toxin in treat-
ment of trigeminal neuralgia and (ii) no restriction on
language, area, publication year, and age of patients. The
exclusion criteria were: (i) unreliably extracted data; (ii)
over-lapped data sets; (iii) book chapters, abstract arti-
cles only, conference papers, reviews, theses, and post-
ers; and (iv) in vitro or animal studies. Any different
decision in screening step was discussed between two re-
viewers to reach a consensus. Consultation from super-
visor (NTH and KH) was acquired if necessary. The full
texts of included references were then retrieved through
the Library of Nagasaki University, and full text screen-
ing was subsequently conducted to identify relevant ref-
erences for data extraction.
Outcome measures
All patients’ outcomes were considered to analyze the
efficacy and safety of botulinum toxin in the treatment
of trigeminal neuralgia: (1) proportion of respondents –
defined as patients with >50 % reduction in mean pain
score from baseline to endpoint; (2) mean paroxysms
frequency per day; (3) mean visual analog scale (VAS)
score at the end of follow up; and (4) adverse events and
complications of BTX A treatment.
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Data extraction
The standardized template was developed through a pilot
extraction with the two most relevant references. Two re-
searchers then independently extracted the data into the
template. Extracted data included: authors, publication year,
journal, country of authors, country of patients, source of
BTX-A, active drug types and their doses, control types and
their doses, number and site of injection, characteristics of
patients (gender and age), duration of treatment, duration
of follow up, year of neuralgia, affected branch, surgical
procedures, efficacy point, proportion of responders, re-
lapse, visual analog scale, number of paroxysms per day,
quality of life, anxiety scale, and depression scale .
Statistical method
Statistical analysis was carried out using RevMan version
5.3 (The Cochrane Collaboration, Oxford, United King-
dom). Continuous data were pooled as mean difference
(MD), while pooled risk ratio (RR) was combined for di-
chotomous data using Mantel-Haenszel (M-H) method.
Fixed effect model was adopted in all analyses. We per-
formed a sensitivity analysis to: (1) investigate the effect of
the model assumed on the overall effect size, by running
the analysis under the random effects model and observing
if a difference exists (2) explore the effect of the study
quality on the summary effect estimate, by omitting stud-
ies rated as "high risk of bias" for both random sequence
generation and allocation concealment. Heterogeneity
was assessed by visual inspection of the forest plots
and measured by I-square and Chi-square tests. P-
values reported in this paper are not adjusted for
multiplicity; however, adequate randomization and
blinding was achieved by most included studies,
ensuring appropriate control for confounders. P-value
< 0.05 was considered statistically significant.
Quality assessment
The methodological quality of each RCT was independ-
ently assessed by two reviewers using "The Cochrane Colla-
boration's tool for assessing risk of bias". It is a two-part
tool, addressing seven specific domains, including: sequence
generation, allocation concealment, blinding of participants
and personnel, blinding of outcome assessment, incomplete
outcome data, selective outcome reporting, and other
sources of bias. The judgment of each reviewer on each do-
main was categorized as ‘low risk,’ ‘high risk,’ or ‘unclear
risk’ of bias. Any disagreement was resolved by discussion
between two reviewers and by consultation from a super-
visor to reach a consensus.
Results
Literature search
A total number of 267 articles were retrieved from six
search engines/libraries (Fig. 1). SIGLE, POPLINE,
NYAM, and ClinicalTrials generated no results. After
the initial title and abstract screening of the 267 arti-
cles, 28 articles were selected for full-text reading.
Two independent reviewers performed the full-text
screening after which 24 articles were excluded due
to: (1) inappropriate study design; (2) unreliably ex-
tracted data; (3) in vitro or animal study; and (4)
posters. Finally, a total of four unique RCTs, with a
total of 178 TN patients, were included for data ex-
traction and final analysis.
Study characteristics
The characteristics of four RCTs included in the final
analysis were summarized in Table 1. A total of 178
patients (99 in the BTX-A group and 79 in the placebo
control group) were included from four trials. The mean
age for both case and control groups in three RCTs [23–
25] was ranging from 58.1 to 64.5 for case group and
from 58 to 66 for control group. There was no signifi-
cant difference between BTX-A and placebo groups in
terms of frequency of attacks and pain severity before
treatment as reported in each included study. The
follow-up period varied from 8 to 12 weeks except for
no report from study of Zhang et al. The mean duration
of the effect was also ranging between 8 to 12 weeks in
two trials [23, 25].
The amount of BTX-A injected, the route of injection,
the number of injections, and the injection site varied
among studies. The amount of BTX-A injected ranged
from a minimum of 25 U in study of Zhang et al. [24] to
a maximum of 100 U in study of Shehata et al. [26]. In
addition, 50 U and 75 U of BTX-A were used in studies
Fig. 1 PRISMA flow diagram of studies’ screening and selection
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of Zúñiga et al. [25] and Wu et al. [23], respectively. The
administration of BTX-A included subcutaneous or
intradermal routes. The details of the injection protocol
in each trial are summarized in Table 2.
Quality assessment
The quality of included studies ranged from medium to
high as illustrated in Fig. 2. Authors’ judgments with
justifications are shown in (Additional file 2: Table S2).
Therapeutic efficacy
Three patients’ therapeutic outcomes include: (1) pro-
portion of respondents – defined as patients with >50 %
reduction in mean pain score from baseline to endpoint;
(2) mean paroxysms frequency per day; and (3) mean
visual analog scale (VAS) score at the end of follow up.
The overall effect favored BTX-A compared with pla-
cebo in terms of proportion of responders (RR = 2.87,
95 % CI [1.76, 4.69], P < 0.0001) with no significant het-
erogeneity detected (P = 0.31; I2 = 4 %) (Fig. 3a). Mean
VAS score was significantly lower for BTX-A group at
the end of the first month (MD = -2.89, 95 % CI [-4.66,–
1.12], P = 0.001), at the end of the 2nd month (MD
= -2.47, 95 % CI [-3.96,–0.99], P = 0.001), and at the end
of the 3rd month of follow up (MD = -3.43, 95 % CI
[-5.21,–1.64], P = 0.0002) with no significant heterogen-
eity detected for all endpoints (Fig. 3b). Mean paroxysms
frequency per day was significantly lower for BTX-A
group (MD= -29.79, 95 % CI [-38.50,–21.08], P < 0.00001)
Table 1 Baseline characteristics of included RCTs
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Table 2 Injection protocol of BTX-A
Author Type of BTX-A Source of BTX-A Amount
of BTX-A
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with no significant heterogeneity (P = 0.21; I2 = 36 %)
(Fig. 3c).
Adverse events
Regarding safety of BTX-A, there were two reported
injection-related side effects: facial asymmetry and edema/
hematoma at the site of injection, and both of which were
generally tolerated and transitory in nature. The overall oc-
currence of facial asymmetry in BTX-A group ranged from
2-5 patients while it ranged between 1–2 for edema/
hematoma. Facial asymmetry recovered within 5–7 weeks
while edema/hematoma resolved within 5–6 days. None of
the controlled patients developed facial asymmetry or
edema/hematoma except two patients in Shehata et al. [26]
and one patient in Wu et al. [23]. The adverse events were
fully summarized in Table 3.
Additional analysis
Only one study [23] had both sequence generation
and allocation concealment rating of "high risk of
bias". Omitting this study from the analysis, slightly
changed the effect estimate and CI but did not have
a serious impact on the findings (Fig. 4). Moreover,
the overall effect estimate did not differ significantly
for any of the outcomes on using the random effects
model (Fig. 5). This in turn adds to the robustness of
the results.
Discussion
Treatment of TN continues to present a clinical appeal
to both patients and health care providers. Medications
(such as antiepileptic drugs) were poorly tolerated. They
effected central nervous system adverse events in a
substantial proportion of patients [27]. As such, re-
fractory cases were approached by alternative surgical
interventions, which yielded marked improvement in
about 63–94 % of cases [28]. Nonetheless, serious
complications of invasive surgery (including aseptic
meningitis and hearing loss) rendered further suffer-
ings to TN patients [28].
Thus safer, well tolerated, and more effective alterna-
tive is imperative for TN. The evidence from this sys-
tematic review suggests that botulinum toxin type A
(BTX-A) has a clinically significant benefit in treatment
of trigeminal neuralgia when compared to placebo in
terms of proportion of responders, the mean paroxysms
frequency per day, and the VAS score at the end of fol-
low up. These overall outcomes consistently favored
BTX-A compared with placebo across studies.
The duration of effect for BTX-A seems to be of rela-
tively long duration (at least 3 months). In Wu et al. [23]
trial, BTX-A was effective within a median follow-up
duration of 90 days. Also, Zuniga et al. [25] showed that
BTX-A was effective during the 3 months follow-up
period. However, a conclusion cannot be made on how
long the effect of BTX-A lasts, and how often recurrent
injections are needed. This raises the need for further
studies with extended follow-up duration that imple-
ment chronic pain measurement scales. A point of vari-
ation is the dosage of BTX-A; the used dosage of BTX-A
in the analyzed RCTs ranged from 25 to 100 U. Zhang
et al. [24] found that lower dose (25 U) and higher dose
(75 U) were similar in efficacy on short-term assessment.
Moreover, a dramatic response to BTX-A was also re-
ported in an open-label trial [29] at a much lower dose
of BTX-A (6.45–9.11 U).
The treatment mechanism of BTX-A in TN remains
unclear. Previous preclinical studies suggested that it
acts locally or on the trigeminal ganglia [30, 31]. Con-
versely, Matak et al. reported a central antinociceptive
effect of BTX-A in a rat model of TN [32, 33]. Wu et al.
recently asserted this notion and proved that peripher-
ally applied BTX-A exerts antinociceptive function via
reducing central sensitization and inhibiting high expres-
sion of nociceptors [34].
It is noteworthy to mention that Yong Hu et al.
[35] approached the same topic with our study,
but they mostly included open-label trials, which
potentially weakened their conclusion. Furthermore,
Fig. 2 Cochrane bias assessment of included studies
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Fig. 3 A Forest plots of relative risk (RR) for proportion of respondents comparing BTX A with placebo. M-H: Mantel-Haenzel, CI: confidence
interval. B Forest plots of mean difference in VAS score comparing BTX A with placebo at the end of follow up (A), 1 month (B), 2 month (C), and
3 month (D). VAS: Visual analogue scale, MD: Mean difference, M-H: Mantel-Haenzel, CI: confidence interval. C Forest plots of mean difference in
number of paroxysm comparing BTX A with placebo. MD: Mean difference, M-H: Mantel-Haenzel, CI: confidence interval
Table 3 Adverse events for all patients in included RCTs
Author/reference Facial asymmetry Edema/hematoma at injection area
Exposed Control Disappearance Exposed Control Disappearance
Zhang et al. [24] 3 0 6 weeks 2 0 5 days
Shehata et al. [26] 4 0 not reported 1 2 not reported
Wu et al [23] 5 0 7 weeks 2 1 7 days
Zúñiga et al [25] 2 0 not reported 2 0 not reported
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by combining one randomized, double-blind, placebo
control trial with five open-label trials, the previous
study possibly introduced some heterogeneity into their
review.
One limitation of the current systematic review was
the small number of trials that investigated the safety
and efficacy of BTX-A in trigeminal neuralgia. There-
fore, we cannot explore the publication bias using
Egger's test for funnel plot asymmetry, we rather
searched clinical trial registries and grey literature and
found only two protocols of ongoing studies. No com-
pleted unpublished studies were retrieved. Missing data
(mean baseline age in Shehata et al. and length of follow
up in Zhang et al.) could not be used to adjust for pos-
sible biases in the aforementioned studies. More double-
blinded RCTs are required to elaborate more on (1) opti-
mal dose of BTX-A, (2) optimal duration of treatment,
and (3) optimal route of administration. In addition, fur-
ther research is needed to explore more on the mechan-
ism of action of BTX-A to relieve pain in trigeminal
neuralgia.
Conclusions
In conclusion, our systematic review suggests that BTX-
A is a promising alternative treatment option that might
spare the need for surgical interventions for refractory
cases of trigeminal neuralgia in the future. Evidence
from larger and well-designed RCTs is still required to
assert upon these findings.
Fig. 4 Forest plots of Sensitivity analysis (random effects model)
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Article highlights
➢ RCTs reporting the efficacy and safety of BTX-A in
the treatment of TN were included for systematic re-
view and meta-analysis.
➢ BTX-A is an effective and safe treatment option for
patients with trigeminal neuralgia.
➢ No serious adverse events or systemic reaction of
BTX-A have been reported.
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